Advertisement

European Journal of Clinical Pharmacology

, Volume 25, Issue 1, pp 23–28 | Cite as

The effect of PK 5078, a new serotonin uptake inhibitor, on serotonin levels and uptake in human platelets, following administration to healthy volunteers

  • M. Kenny
  • T. J. Lenehan
  • R. Lambe
  • I. Brick
  • A. Darragh
  • C. Maulet
Originals

Summary

PK 5078 is a recently developed compound which inhibits specifically the neuronal reuptake of serotonin and enhance its release. PK 5078 was administered to healthy male volunteers in single and multiple oral doses and the effects on platelet serotonin uptake and content were examined. A significant dose-related inhibition of 3H-serotonin uptake by platelets was observed following single oral doses of PK 5078 (25–150 mg), with maximal inhibition at 75 mg. This was evident 2 h after dosing and was still marked after 10 h. Plasma collected from the subjects after dosing also had a considerable dose-related effect on the uptake of 3H-serotonin by untreated platelets. No significant alteration in platelet serotonin content was observed after single doses of PK 5078. When PK 5078 (50 mg) was administered twice daily for 9 days there was a rapid and sustained reduction in 3H-serotonin uptake by platelets, which returned to pretreatment levels 2 days after discontinuation of the drug. A similar response was observed when plasma from these subjects was incubated with untreated platelets. The rate of depletion of endogenous platelet serotonin was much slower with minimum levels being attained on the morning after the final dose. The recovery following withdrawal was also slow with serotonin levels approaching pre-dose values 14 days after the final dose of PK 5078.

Key words

antidepressant PK 5078 serotonin platelet 5-HT uptake platelet 5-HT content plasma 5-HT level side effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aberg-Wistedt A, Jostell K-G, Ross SK, Westerlund D (1981) Effect of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression. Psychopharmacology 74: 297–305Google Scholar
  2. Buus Lassen J, Lund J, Bechgaard E, Sondergaard I (1979) Inhibition of 5-HT uptake into neurons and platelets in mice treated chronically with clorimipramine and femoxetine. Psychopharmacology 64: 149–153Google Scholar
  3. Ebbe S (1971) Origin, production and life span of blood platelets. In: Johnson SA (ed) The circulating platelet. Academic Press, New York pp 19–43Google Scholar
  4. Ehsanullah RSB (1980) Uptake of 5-hydroxytryptamine and dopamine into platelets from depressed patients and normal subjects — influence of clomipramine, desmethylclomipramine and maprotiline. Postgrad Med J 56 [Suppl 1]: 31–35Google Scholar
  5. Gordon JL, Olverman HJ (1978) 5-Hydroxytryptamine and dopamine transport by rat and human blood platelets. Br J Pharmacol 62: 219–226Google Scholar
  6. Lemberger L, Rowe H, Carmichael R, Crabtree R, Horng JS, Bymaster F, Wong D (1978) Fluoxetine, a selective serotonin uptake inhibitor. Clin Pharmacol Ther 23: 421–429Google Scholar
  7. Lenehan T, Omer LMO, Kenny M, Lambe R, Darragh A (1981) The effects of multiple rising doses of Ro 11-2465 (serotonin uptake inhibitor) on serotonin content of human platelets. Psychopharmacology 74: 1–3Google Scholar
  8. Lingjaerde O (1979) Inhibition of platelet uptake of serotonin in plasma from patients treated with clomipramine and amitriptyline. Eur J Clin Pharmacol 15: 335–340Google Scholar
  9. Lund J, Lomholt B, Fabricius J, Christensen JA, Bechgaard E (1979) Paroxetine: Pharmacokinetics, tolerance and depletion of blood 5-HT in man. Acta Pharmacol Toxicol 44: 289–295Google Scholar
  10. Pletscher A (1968) Metabolism, transfer and storage of 5-hydroxytryptamine in blood platelets. Br J Pharmacol Chemother 32: 1–6Google Scholar
  11. Pletscher A (1978) Platelets as models for monoaminergic neurons. In: Youdim MBH (ed) Essays in neurochemistry and neuropharmacology; Vol 3 Wiley, London, p 49Google Scholar
  12. Ross SB, Aperia B, Beck-Friis J, Jansa S, Wetterberg L, Aberg A (1980) Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo. Psychopharmacology 67: 1–7Google Scholar
  13. Stahl SM (1977) The human platelet. Arch Gen Psychiatry 34: 509–516Google Scholar
  14. Stahl SM, Meltzer HY (1978) A kinetic and pharmacological analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: Comparison with central serotonergic neurons. J Pharmacol Exp Ther 205: 118–132Google Scholar
  15. Tuomisto J (1974) A new modification for studying 5-HT uptake by blood platelets: A re-evaluation of tricyclic antidepressants as uptake inhibitors. J Pharm Pharmacol 26: 92–100Google Scholar
  16. Tuomisto J, Tukiainen E, Ahlfors UG (1979) Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmacology 65: 141–147Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • M. Kenny
    • 1
  • T. J. Lenehan
    • 1
  • R. Lambe
    • 1
  • I. Brick
    • 1
  • A. Darragh
    • 1
  • C. Maulet
    • 2
  1. 1.Institute of Clinical PharmacologyDublinIreland
  2. 2.Pharmuka Laboratoires, Recherche et DeveloppementGennevilliersFrance

Personalised recommendations